|Day Low/High||2.68 / 2.75|
|52 Wk Low/High||1.46 / 7.29|
Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment
These stocks look ready to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016
Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions
Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies